Anti-Rheumatic Drugs - Switzerland

The Anti-Rheumatic Drugs market in Switzerland is expected to witness significant growth in the coming years.
By 2024, the projected revenue in this market is estimated to reach US$174.50m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 0.66%, resulting in a market volume of US$180.30m by 2029.
When compared to other countries globally, United States is forecasted to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, it is projected to reach an impressive US$34.70bn.
Switzerland's pharmaceutical industry dominates the market for anti-rheumatic drugs with its cutting-edge research and development.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Switzerland has been experiencing a steady growth in recent years.

Customer preferences: Swiss customers have shown a growing preference for biologic drugs, which have a higher efficacy rate and are more targeted in treating rheumatoid arthritis. Additionally, there is a rising demand for self-administered drugs, which are more convenient and offer greater flexibility to patients.

Trends in the market: The Swiss Anti-Rheumatic Drugs market is expected to continue on its growth trajectory, driven by an aging population and increasing prevalence of rheumatoid arthritis. Moreover, the market is witnessing a shift towards personalized medicine, with the development of new biologic drugs that target specific molecular pathways. This trend is expected to continue in the coming years, as research and development efforts focus on developing more targeted and effective treatments.

Local special circumstances: Switzerland has a strong healthcare system, which provides universal coverage and high-quality care. This has led to a high level of patient awareness and a willingness to adopt new treatments. Additionally, the country has a well-developed pharmaceutical industry, with many global players having a significant presence in the market. This has led to a high level of competition and innovation, with companies investing heavily in research and development to stay ahead of the curve.

Underlying macroeconomic factors: Switzerland has a strong and stable economy, with a high per capita income and a low unemployment rate. This has led to a high level of disposable income among consumers, which has translated into higher spending on healthcare. Additionally, the country has a well-developed infrastructure and a high level of technological advancement, which has facilitated the development and adoption of new treatments.In conclusion, the Anti-Rheumatic Drugs market in Switzerland is expected to continue on its growth trajectory, driven by increasing demand for biologic drugs and a shift towards personalized medicine. The country's strong healthcare system, competitive market, and favorable macroeconomic factors provide a conducive environment for the development and adoption of new treatments.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.